Insights

For years, the conversation about accelerating drug development has focused on scientific discovery: better target identification, faster molecule design, stronger predictive models, and, more recently, the growing role of artificial intelligence (AI). AI investment is now beginning to change the front end of the pipeline. More candidates can now be identified, prioritized, and advanced with unprecedented speed in the preclinical space. But that progress has exposed a different constraint: how to evaluate these promising therapies as they transition into humans at a pace the current clinical development system can sustain.

Pediatric research is essential to improving child health worldwide. However, scientific, ethical, and infrastructural challenges serve as barriers to this essential research. International and national stakeholders have developed coordinated strategies to strengthen evidence generation, enhance safety assessments, and accelerate therapeutic discovery for children.

According to the authors of this Letter to the Editor, ensuring robust female representation in both clinical and observational studies is vital for producing generalizable findings and improving women’s health. Despite significant efforts to include women and minorities in clinical research, persistent gaps in participation still exist. A key challenge lies in balancing participation with safety measures designed to protect female participants, particularly those of childbearing potential, from the risks associated with certain inventions and/or exposures.